Carcinoma, Non-Small-Cell Lung

- Ability to understand and willingness to sign a written Informed Consent
- Advanced relapsed or refractory predominantly non squamous NSCLC. The diagnosis must have been confirmed cyto-/ histologically
- Patients must have measurable or non-measurable disease
- At least two but not more than three prior standard treatment regimens for NSCLC
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Male or female subjects >/= 18 years of age (>/=20 for Japan) at the time of Informed Consent
- Life expectancy of at least 12 weeks
- Ability to swallow oral medication
- Both men and women using adequate barrier birth control measures during the course of the trial and 4 weeks after the completion of trial
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of the study drug:
 -- Haemoglobin > 9.0 g/dl
 -- Absolute neutrophil count (ANC) >1,500/mm3
 -- Platelet count >/= 100,000/µl
 -- Total bilirubin  -- Alanine aminotransferase (ALT) < 2.5 x upper limit of normal (Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (  -- Alkaline phosphatase < 4 x upper limit of normal (  -- Prothrombin Time (PT)-International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) < 1.5 x upper limit of normal
 -- Serum creatinine < 1.5 x upper limit of normal
 -- Calculated creatinine clearance of >/= 50 mL/min

- NSCLC patients with predominantly squamous cell carcinoma histology
Excluded medical conditions:
- History of cardiac disease: Congestive heart failure, Active coronary artery disease (CAD), Cardiac arrhythmias (>Grade 2 NCI-CTCAE [National Cancer Institute-Common Terminology Criteria for Adverse Events] vers. 3.0)
- Uncontrolled hypertension despite two anti-hypertensive medications
- History of Human immunodeficiency virus (HIV) infection or chronic hepatitis B
or C
- History of organ allograft
- Active clinically serious infections (> grade 2 NCI-CTCAE vers. 3.0)
- Patients with seizure disorder requiring medication
- Patients with evidence or history of bleeding diathesis or coagulopathy
- Patients undergoing renal dialysis
- Pulmonary hemorrhage/ bleeding event >/= CTCAE grade 2 within four weeks prior to the first dose of the study drug
- Any other hemorrhage/ bleeding event >/= CTCAE grade 3 within four weeks prior to the first dose of the study drug
- Thrombotic or embolic venous or arterial events such as cerebrovascular accident
- Pregnant or breast-feeding women.
- Any condition which could affect the absorption or pharmacokinetics of the study drug
- Prior treatment with other Vascular Endothelial Growth Factor (VEGF) (R) inhibitors, including compounds that impact vascularity (i.e. sunitinib, thalidomide, vandetanib, vascular disrupting agents [VDA], VEGF-trap and other experimental agents of this class). Only bevacizumab (Avastin) is permitted.